AML patients defined as favourable risk (containing CEBPA and/or MPN1 without FLT3-ITD) by the European Leukaemia Net (ELN) will display worse EFS in the presence of TET2 mutations (10 months vs. 41.3 months) [41]. The gene discussed is TET2; the disease is acute myeloid leukemia.